The hepatic-specific miRNA-122, which is the target of miravirsen, has been shown to be reduced in hepatic fibrosis in cells [66]; however, the circulating serum levels of miRNA-122 are elevated significantly in fibrosis and this correlates with serum alanine aminotransferase (ALT) levels, a marker of damaged liver [67] and may be a more reliable marker than ALT in assessing fibrosis [67] and has been found in other independent cohorts [68]. The gene discussed is GPT; the disease is fibrosis.